MX2016013341A - Agentes antiinflamatorios como compuestos virostaticos. - Google Patents

Agentes antiinflamatorios como compuestos virostaticos.

Info

Publication number
MX2016013341A
MX2016013341A MX2016013341A MX2016013341A MX2016013341A MX 2016013341 A MX2016013341 A MX 2016013341A MX 2016013341 A MX2016013341 A MX 2016013341A MX 2016013341 A MX2016013341 A MX 2016013341A MX 2016013341 A MX2016013341 A MX 2016013341A
Authority
MX
Mexico
Prior art keywords
virus
compounds
virostatic
inflammatory agents
hhv
Prior art date
Application number
MX2016013341A
Other languages
English (en)
Inventor
Strobl Stefan
Original Assignee
Panoptes Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptes Pharma Gmbh filed Critical Panoptes Pharma Gmbh
Publication of MX2016013341A publication Critical patent/MX2016013341A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula general (I) y las sales y los derivados fisiológicamente funcionales de los mismos, (ver Fórmula) para usar en el tratamiento de enfermedades causadas por un adenovirus, el VHH (virus del herpes humano), VVZ (virus de la varicela zóster), VHS (virus del herpes simple), VEB (virus de Epstein-Barr), virus de vaccinia, o virus BK.
MX2016013341A 2014-04-11 2014-04-11 Agentes antiinflamatorios como compuestos virostaticos. MX2016013341A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/057398 WO2015154820A1 (en) 2014-04-11 2014-04-11 Anti-inflammatory agents as virostatic compounds

Publications (1)

Publication Number Publication Date
MX2016013341A true MX2016013341A (es) 2017-09-01

Family

ID=50483370

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013341A MX2016013341A (es) 2014-04-11 2014-04-11 Agentes antiinflamatorios como compuestos virostaticos.

Country Status (8)

Country Link
US (1) US9795590B2 (es)
JP (1) JP6271806B2 (es)
KR (1) KR102265277B1 (es)
AU (1) AU2014390300A1 (es)
CA (1) CA2944570A1 (es)
MX (1) MX2016013341A (es)
RU (1) RU2016144238A (es)
WO (1) WO2015154820A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201608835VA (en) * 2014-05-08 2016-11-29 Panoptes Pharma Ges M B H Compounds for treating ophthalmic diseases and disorders
TW201834649A (zh) 2017-03-02 2018-10-01 新加坡商亞獅康私人有限公司 癌症療法
EP3594205A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-aryl derivatives for treating a rna virus infection
CN112996789A (zh) 2018-09-12 2021-06-18 诺华股份有限公司 抗病毒吡啶并吡嗪二酮化合物
CN109701024B (zh) * 2019-03-04 2020-12-11 复旦大学 Bk通道开放剂的新用途
KR20220070005A (ko) 2019-09-26 2022-05-27 노파르티스 아게 항바이러스성 피라졸로피리디논 화합물
EP3892268B1 (en) * 2020-04-10 2022-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of vidofludimus for the treatment of coronavirus infections
AU2021260040A1 (en) 2020-04-21 2022-11-17 Immunic Ag Vidofludimus for use in the treatment or prevention of viral diseases
WO2022045984A1 (en) * 2020-08-31 2022-03-03 Aslan Pharmaceuticals Pte Ltd Treatment and/or prevention of a viral infection
WO2022196236A1 (ja) * 2021-03-18 2022-09-22 国立大学法人 鹿児島大学 抗薬剤耐性インフルエンザウイルス剤及び抗薬剤耐性インフルエンザウイルス剤の製造のための化合物の使用
KR20240007144A (ko) 2021-04-09 2024-01-16 이뮤닉 아게 중수소화 dhodh 억제제
IL313501A (en) 2021-12-23 2024-08-01 Immunic Ag DHODH INHIBITORS CONTAINING CARBOXYLIC ACID BIOISOSTERE
US20230278979A1 (en) * 2022-03-01 2023-09-07 Kiora Pharmaceuticals Gmbh Salts of a dihydroorotate dehydrogenase (dhod) inhibitor
WO2023172818A1 (en) * 2022-03-09 2023-09-14 Kiora Pharmaceuticals Gmbh Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor
WO2023232884A1 (en) 2022-06-01 2023-12-07 Immunic Ag Treatment of ulcerative colitis comprising vidofludimus or a pharmaceutically acceptable salt thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
ATE450498T1 (de) * 2002-12-23 2009-12-15 4Sc Ag Cycloalken-dicarbonsäure-verbindungen als entzündungshemmende, immunmodulatorische und antiproliferative mittel
WO2004056747A1 (en) 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
WO2004056746A1 (en) 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
TWI530286B (zh) * 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑

Also Published As

Publication number Publication date
JP6271806B2 (ja) 2018-01-31
KR102265277B1 (ko) 2021-06-16
US9795590B2 (en) 2017-10-24
US20170027905A1 (en) 2017-02-02
RU2016144238A3 (es) 2018-05-11
RU2016144238A (ru) 2018-05-11
JP2017513935A (ja) 2017-06-01
KR20160136453A (ko) 2016-11-29
CA2944570A1 (en) 2015-10-15
WO2015154820A1 (en) 2015-10-15
AU2014390300A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
MX2016013341A (es) Agentes antiinflamatorios como compuestos virostaticos.
EP3774775B8 (en) 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
EA201790921A1 (ru) Замещенные производные 2-анилинпиримидина в качестве модуляторов egfr
IN2015DN01156A (es)
AU2013328732A8 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
EP3244932A4 (en) Rna guided eradication of herpes simplex type i and other related herpesviruses
MX2014005304A (es) Biaril eter sulfonamidas y su uso como agentes terapeuticos.
NZ711896A (en) Compounds and methods for kinase modulation, and indications therefor
BR112017005104A2 (pt) derivado de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina
IN2014CN03337A (es)
MX2015001829A (es) Derivados de alquilpirimidina para el tratamiento de infecciones viricas y otras enfermedades.
PH12015502737A1 (en) Novel fused pyrimidine compound or salt thereof
ES2529143R1 (es) Combinacion de al menos dos agentes antivirales de accion directa, ribavirina pero no interferon para uso de tratamiento del vhc
MX2015010125A (es) Derivados de piridazinona-amidas.
MX352564B (es) Compuestos heterociclos biciclicos y sus usos en terapia.
MX2017007429A (es) Derivados de pirazolo[1,5-a]pirimidina sustituida con piperidina con actividad inhibidora sobre la replicacion del virus sincicial respiratorio (vsr).
CO7131375A2 (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112015026721A2 (pt) derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer
IN2014MN02056A (es)
MX341728B (es) Derivados sulfonamido de 3, 4/diarilpirazoles como inhibidores de proteina quinasa.
AU2015295120A8 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
MX340622B (es) Formulaciones antivirales topicas para prevencion de transmision de hsv-2.